| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $25,275,008 | 2 | 29 |
Sells | $246,038 | 5 | 71 |
| Apeiron Investment Group Ltd. | 10 percent owner | 2 | $25.28M | 0 | $0 | $25.28M |
| Craig Kevin James | Chief Medical Officer | 0 | $0 | 1 | $15,610 | $-15,610 |
| Short Glenn Frank | Chief Scientific Officer | 0 | $0 | 1 | $17,767 | $-17,767 |
| Johnson Anne Nagengast | Chief Financial Officer | 0 | $0 | 1 | $45,286 | $-45,286 |
| Kirpekar Sahil | Chief Business Officer | 0 | $0 | 1 | $65,560 | $-65,560 |
| Rao Srinivas | See Remarks | 0 | $0 | 1 | $101,814 | $-101,814 |
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Over the last 12 months, insiders at Atai Life Sciences N.V. have bought $25.28M and sold $246,038 worth of Atai Life Sciences N.V. stock.
On average, over the past 5 years, insiders at Atai Life Sciences N.V. have bought $12.53M and sold $383,757 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Apeiron Investment Group Ltd. (10 percent owner) — $25.28M.
The last purchase of 1,800,000 shares for transaction amount of $2.52M was made by Apeiron Investment Group Ltd. (10 percent owner) on 2025‑03‑24.
| 2025-03-24 | Apeiron Investment Group Ltd. | 10 percent owner | 1.8M 0.8274% | $1.40 | $2.52M | -8.44% | ||
| 2025-03-21 | Sale | Rao Srinivas | See Remarks | 75,418 0.0362% | $1.35 | $101,814 | -0.34% | |
| 2025-03-21 | Sale | Johnson Anne Nagengast | Chief Financial Officer | 33,545 0.0161% | $1.35 | $45,286 | -0.34% | |
| 2025-03-21 | Sale | Kirpekar Sahil | Chief Business Officer | 48,563 0.0233% | $1.35 | $65,560 | -0.34% | |
| 2025-03-21 | Sale | Short Glenn Frank | Chief Scientific Officer | 13,161 0.0063% | $1.35 | $17,767 | -0.34% | |
| 2025-03-21 | Sale | Craig Kevin James | Chief Medical Officer | 11,563 0.0055% | $1.35 | $15,610 | -0.34% | |
| 2025-02-14 | Apeiron Investment Group Ltd. | 10 percent owner | 10.84M 5.9738% | $2.10 | $22.76M | -36.09% | ||
| 2024-05-16 | Sale | Brand Florian | See Remarks | 151,303 0.09% | $1.92 | $290,502 | -24.73% | |
| 2024-04-02 | Sale | Rao Srinivas | See Remarks | 61,640 0.0367% | $1.85 | $114,034 | -21.93% | |
| 2024-04-02 | Sale | Johnson Anne Nagengast | Chief Financial Officer | 27,410 0.0163% | $1.85 | $50,709 | -21.93% | |
| 2024-04-02 | Sale | Kirpekar Sahil | Chief Business Officer | 35,801 0.0213% | $1.85 | $66,232 | -21.93% | |
| 2023-11-16 | Brand Florian | See Remarks | 20,000 0.0125% | $1.16 | $23,120 | +33.33% | ||
| 2023-09-13 | Brand Florian | See Remarks | 40,000 0.0242% | $1.45 | $57,968 | +3.19% | ||
| 2023-03-29 | Apeiron Investment Group Ltd. | 10 percent owner | 1.21M 0.6461% | $1.32 | $1.6M | +8.80% | ||
| 2023-03-29 | Brand Florian | See Remarks | 70,000 0.0418% | $1.48 | $103,558 | +8.80% | ||
| 2022-04-28 | Angermayer Christian | 21,900 0.0144% | $4.47 | $97,801 | -28.96% | |||
| 2022-04-26 | Angermayer Christian | 19,803 0.013% | $4.64 | $91,939 | -31.30% | |||
| 2022-04-22 | Angermayer Christian | 52,820 0.0346% | $4.83 | $254,962 | -33.79% | |||
| 2022-04-20 | Angermayer Christian | 68,688 0.0434% | $4.95 | $340,040 | -37.52% | |||
| 2022-04-18 | Angermayer Christian | 54,322 0.0353% | $5.11 | $277,656 | -37.38% |
| Apeiron Investment Group Ltd. | 10 percent owner | 42369415 21.149% | $86.86M | 4 | 0 | <0.0001% |
| Rao Srinivas | See Remarks | 212942 0.1063% | $436,531.10 | 1 | 2 | <0.0001% |
| Johnson Anne Nagengast | Chief Financial Officer | 140045 0.0699% | $287,092.25 | 0 | 2 | |
| Kirpekar Sahil | Chief Business Officer | 115636 0.0577% | $237,053.80 | 0 | 2 | |
| Short Glenn Frank | Chief Scientific Officer | 42333 0.0211% | $86,782.65 | 0 | 1 | |
| Craig Kevin James | Chief Medical Officer | 8437 0.0042% | $17,295.85 | 0 | 1 | |
| Auerbach Michael | director | 5564474 2.7775% | $11.41M | 1 | 0 | <0.0001% |
| Angermayer Christian | 1799302 0.8981% | $3.69M | 9 | 0 | <0.0001% | |
| Brand Florian | See Remarks | 328697 0.1641% | $673,828.85 | 4 | 1 | <0.0001% |
| WEAVER GREGORY L | Chief Financial Officer | 4666 0.0023% | $9,565.30 | 1 | 0 | <0.0001% |
| Kalali Amir H | director | 4666 0.0023% | $9,565.30 | 1 | 0 | <0.0001% |
| Smiley Andrea Heslin | director | 4666 0.0023% | $9,565.30 | 1 | 0 | <0.0001% |
| de Rosnay Alexis | director | 4666 0.0023% | $9,565.30 | 1 | 0 | <0.0001% |
$587,109,125 | 90 | 3.17% | $416.2M | |
$5,911,307 | 70 | -1.38% | $441.24M | |
$1,443,732 | 36 | 10.14% | $465.2M | |
Atai Life Sciences N.V. (ATAI) | $24,857,912 | 21 | -35.40% | $410.69M |
$26,923,982 | 20 | -17.22% | $362.61M | |
$6,280,187 | 19 | 6.80% | $446.49M | |
$111,056,143 | 19 | -7.49% | $427.32M | |
$109,488,423 | 15 | 56.69% | $392.4M | |
$46,442,839 | 15 | -20.05% | $386.25M | |
$152,858,569 | 14 | -4.66% | $410.95M | |
$7,254,955 | 14 | 20.70% | $359.59M | |
$3,073,199 | 10 | 16.77% | $403.28M | |
$135,543,039 | 9 | -5.28% | $442.01M | |
$19,420,853 | 5 | 4.35% | $403.07M | |
$356,211 | 4 | 32.45% | $359.09M | |
$602,180 | 4 | -26.17% | $357.75M | |
$8 | 2 | 28.83% | $356.61M | |
$3,250,000 | 1 | -44.91% | $416.15M | |
$504,640 | 1 | 16.84% | $424.44M |
| Increased Positions | 27 | +24.55% | 9M | +65.16% |
| Decreased Positions | 37 | -33.64% | 2M | -14.31% |
| New Positions | 9 | New | 2M | New |
| Sold Out Positions | 16 | Sold Out | 899,053 | Sold Out |
| Total Postitions | 100 | -9.09% | 22M | +50.85% |
| Morgan Stanley | $4,996.00 | 1.67% | 3.33M | +292,374 | +9.62% | 2024-12-31 |
| Ubs Group Ag | $2,909.00 | 0.97% | 1.94M | +2M | +7,249% | 2024-12-31 |
| Millennium Management Llc | $1,472.00 | 0.49% | 981,557 | +539,830 | +122.21% | 2024-12-31 |
| Davidson Kempner Capital Management Lp | $1,424.00 | 0.48% | 949,373 | +949,373 | New | 2024-12-31 |
| Brown University | $1,078.00 | 0.36% | 718,500 | 0 | 0% | 2025-03-31 |
| Woodline Partners Lp | $844.00 | 0.28% | 562,372 | +27,325 | +5.11% | 2024-12-31 |
| Pale Fire Capital Se | $746.00 | 0.25% | 497,402 | +460,018 | +1,230.52% | 2024-12-31 |
| Citadel Advisors Llc | $625.00 | 0.21% | 416,772 | +416,772 | New | 2024-12-31 |
| Vanguard Group Inc | $601.00 | 0.2% | 400,560 | -7,124 | -1.75% | 2024-12-31 |
| Two Sigma Investments, Lp | $586.00 | 0.2% | 390,877 | -16,306 | -4% | 2024-12-31 |